Skip to content

Apnimed

US · APMD #3463 by market cap Listed 2026
16.09 -1.16 -6.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 17.05 -1.13%
After-hours 16.09 0.00%
32.5514.1616.092026-07-312026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on APMD?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -43.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 3.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation B+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 4.1x Better than 98%
Price / Sales 6.1x Better than 18%
P/E vs own 5-yr range 35th pctl Better than 72%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 82.6% Better than 92%
Operating margin -139.9% Better than 7%
Net margin -2.4% Better than 22%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -42.6% Better than 9%
Distance below 52-week high 54.4% Better than 15%
Financial Health F

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 0.4x Better than 1%
Debt to assets 57.0% Better than 10%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 212.8% Better than 95%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.91%
1M -13.07%
3M -43.64%

Key statistics

Price & volume

Prev close
17.25
Open
17.08
Day range
15.95 - 17.73
Avg price
16.34
Volume
248.59K
Turnover
4.06M
Amplitude
10.30%
52-week range
13.88 - 35.29

Valuation

P/E
-5.00
P/E (TTM)
4.13
P/B
2.35
EPS
-3.22
Net profit
-134.01M
Net assets
284.75M

Share structure

Market cap
669.84M
Float cap
193.08M
Shares out
41.63M
Float shares
12.00M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2026-07-31
52-week range 10% of range
13.88 35.29

54.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-1.58M net over the window

Short interest

Shares short
1.59M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Apnimed (APMD)?

Apnimed last traded at 16.09. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Apnimed's market cap?

About 669.84M.

What is the P/E ratio of Apnimed?

The trailing twelve-month P/E is 4.13. The Valuation tab shows it against the stock's own five-year range.

Does Apnimed pay a dividend?

Apnimed does not currently pay a regular dividend.

Is Apnimed a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 50.33, which implies 212.8% upside from the current price. This is not investment advice.

What is Apnimed's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Apnimed a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Apnimed discussion 0 comments

Add a comment